Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

Slides:



Advertisements
Similar presentations
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Advertisements

Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology,
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
NSABP PROTOCOL C-10: RESULTS A Phase II Trial of 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) Plus Bevacizumab for Patients with Unresectable.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
Hot topics in breast radiotherapy Mark Beresford.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer Ignace Vergote, MD PhD University Hospitals Leuven, Belgium IGCS Santa.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
First-Line TKI Use in EGFR Mutation-Positive NSCLC
AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)
Cancer Center Stanford University Gynecologic Cancer Treatment ASCO 2006 Update: Gynecologic Cancers Amreen Husain, M.D. Assistant Professor Division of.
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Endometrial Carcinoma
Are there benefits from chemotherapy to early endometrial cancer
Primary Debulking for Bulky Advanced Stage Ovarian Cancer Ginger J. Gardner, MD Director, Survivorship Program Gynecology Service, Department of Surgery.
Lymphadenectomy in Epithelial Ovarian Cancer
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Gynecologic Malignancies Dr. David Edelmann Sharett Institute of Oncology Hadassah Medical Organization.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Clique para editar o título mestre. Incorporation of bevacizumab in first-line treatment of advanced ovarian cancer: results and indications Ursula Matulonis,
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
Chemotherapy in advanced ovarian cancer Angiolo Gadducci Department of Gynecology and Obstetrics, Unit of Gynecologic Oncology, University of Pisa Rome.
WHAT WILL THE KEY ISSUES IN END- POINT ASSESSMENT BE, IN FUTURE OVARIAN CANCER TRIALS INVOLVING NOVEL TARGETED AGENTS? first line treatment maintenance/consolidation.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Dr Marco Matos Medical Oncologist Gold Coast Cancer Care, Gold Coast University Hospital and, Pacific Private Oncology Group.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
David Cibula, VFN Innovation in surgical approach of ovarian cancer David Cibula Gynecologic Oncology Centre General Faculty Hospital in Prague.
Elderly Women Ovarian Cancer Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt.
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
ELIGIBILITY CRITERIA- Summarised
Randomized Phase III Study Of Gemcitabine
NEOADJUVANT CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CANCER
Adjuvant chemotherapy for early stage epithelial ovarian cancer
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues
Figure #1 Overall survival Figure #2 Disease free survival
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
Farletuzumab in platinum sensitive ovarian cancer with low CA125
Surgery in Stage IIb-IV Ovarian Carcinoma
ASCO Recap Palak Desai, MD.
Ovarian Cancer: The Last 20 Years – The Next 20 Years
OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:
HEPATIC RESECTION FOR PARENCHIMATOUS OVARIAN CANCER LIVER METASTASES BEYOND SECONDARY CYTOREDUCTION FOR RELPASED OVARIAN CANCER Nicolae Bacalbasa1,
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
What is the role of genetic testing in patients with ovarian cancer?
Effect of NACT on optimal debulking in advanced EOC-A retrospective study at a tertiary cancer centre Investigator: Dr.Rekha.B.R Fellow-gynec onco Guide:
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Presentation transcript:

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design

Key Issue #1 What are the most current consensus recommendations on developing large phase III trials in ovarian cancer? What are the most current consensus recommendations on developing large phase III trials in ovarian cancer?

3 rd International Ovarian Cancer Consensus Conference 3 rd - 5 th September 2004, Black Forest, Germany 1-A 1:Is there a need to strictly define the extent and type of surgery for patients in first-line trials? Tissue should be obtained for histopathologic diagnosis to confirm the presence of primary ovarian or peritoneal carcinoma. Staging should be performed according to FIGO guidelines. For example, this includes at least lymph node sampling and peritoneal staging in early stage invasive disease (FIGO I – IIA). Up-front maximal surgical effort at cytoreduction with the goal of no residual disease should be undertaken. Level of Acceptance: 13 / 13

3 rd International Ovarian Cancer Consensus Conference 3 rd - 5 th September 2004, Black Forest, Germany 4-A4:Which regimen / kind of regimens can be regarded as standard comparator for future first-line trials? Within a given trial the chemotherapy regimen should be standardized and consistent with respect to drugs, dose, and schedule. The recommended standard comparator for trials on medical treatment in advanced ovarian cancer (FIGO IIB-IV) is carboplatin- paclitaxel The recommended regimen is carboplatin with a dose of AUC and paclitaxel 175 mg/m²/ 3h given every three weeks for 6 courses Level of Acceptance: 13 / 13

Randomised EORTC-GCG/NCIC-CTG trial on NACT + IDS versus PDS Per protocol population (PP1) ITTPDS N = 361 NACT -> IDS N = 357 Disabling disease11 Histology41 Disease stage32 CA125/CEA ratio13 No pelvic mass-FNA10 Did not start allocated R/135 Other96 Remaining (PP1)329339

AIOM 2000 GOG 182: OS based on Residual Disease

Multivariate analysis for OS(PP1) P values Optimal debulking Histological type (9 categories) Largest tumor size at randomisation Figo Stage (IIIc vs IV) Country (14 categories) Age WHO PSNS Differentiation GradeNS Treatment armNS

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS

AIOM 2000 NACT + IDS versus PDS: ITT Median survial PDS: 29 months IDS: 30 months HR for IDS:0.98 (0.85, 1.14)

GOG0182-ICON5: Overall Survival Median OS and HR (95% CI) ( ) ( ) ( ) ( ) Bookman, ASCO 2006, #5002

GOG 172 – IV vs. IP Overall survival

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS Question # 1: Can we develop a rational superiority trial incorporating neoadjuvant chemotherapy?

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity

Randomised EORTC-GCG/NCIC-CTG trial on NACT + IDS versus PDS Surgical characteristics (PP1) PDS (n = 329) NACT -> IDS (n = 339)* Postoperative mortality (< 28 days) 2,7%0,6% Postoperative sepsis8%2% Fistula (bowel/GU)1,2% / 0,3%0,3% / 0,6% Operative time (minutes)180 Red blood cell transfusion51%53% Hemorhage Grade 3/47%1% Venous Gr 3/42,4%0,3%

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Question # 2: What is the best trial design based on a primary endpoint of QOL?

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will allow more patients to receive optimal surgery and optimal chemotherapy Neoadjuvant chemotherapy will allow more patients to receive optimal surgery and optimal chemotherapy

Randomised EORTC-GCG/NCIC-CTG trial on NACT+ IDS versus PDS Protocol Compliance (PP1) PDS (n = 329) NACT -> IDS (n = 339) Primary debulking100 %0% Interval debulking19%90% Second look surgery5%4% At least 6 courses CT83%86%

AIOM 2000 GOG 182: Residual Disease after Primary Surgery

Randomised EORTC-GCG/NCIC-CTG trial on NACT + IDS versus PDS Surgical findings and results (PP1) PDS (n = 329) NACT -> IDS (n = 339)* Metastases before > 2 cm95%68% Metastases before > 10 cm62%27% No residual after surgery21%53% ≤ 1 cm after surgery46%82% * % calculated on the 306 patients who underwent IDS.

Key Issue # 2 What is the primary hypothesis? What is the primary hypothesis? Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will improve OS or PFS Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will achieve the same survival with a lower operative morbidity Neoadjuvant chemotherapy will allow more patients to receive optimal surgery and optimal chemotherapy Neoadjuvant chemotherapy will allow more patients to receive optimal surgery and optimal chemotherapy Question # 3: Is there a patient population where this would have an impact on outcome?

Key Issue # 3 Neoadjuvant chemotherapy should be applied to all advanced ovarian cancer patients Neoadjuvant chemotherapy should be applied to all advanced ovarian cancer patientsOR Neoadjuvant chemotherapy should be only for select populations: Neoadjuvant chemotherapy should be only for select populations: Elderly Elderly Poor performance status Poor performance status Extensive disease Extensive disease Medical co-morbidities Medical co-morbidities

GOG 182 Median age on trial 58 (62 in neoadjuvant trial) Median age on trial 58 (62 in neoadjuvant trial) Only 14% of patients ≥ 70 Only 14% of patients ≥ 70 Less than 5% ≥ 75 Less than 5% ≥ 75 Performance status 0, 1, 2 Performance status 0, 1, 2 15% were stage IV 15% were stage IV Clearly a large patient population is not being enrolled onto current trials due to advanced age and poor performance status

Key Issue # 3: Special Populations Question # 4: How to best determine extensive disease? Question # 4: How to best determine extensive disease? Radiographic, CA-125 Radiographic, CA-125 Question # 5: What is the best way to incorporate neoadjuvant chemotherapy into advanced age and poor performance populations? Question # 5: What is the best way to incorporate neoadjuvant chemotherapy into advanced age and poor performance populations? Endpoints Endpoints Inclusive study design Inclusive study design

Key Issue # 4: Surgical Timing Question # 6: What is the best timing for surgery in patients undergoing neoadjuvant chemotherapy (3 vs. 6 months)? Question # 6: What is the best timing for surgery in patients undergoing neoadjuvant chemotherapy (3 vs. 6 months)? Which patients should not undergo surgical intervention? Which patients should not undergo surgical intervention?

Key Issue # 5: Endpoints Question # 7: What are the appropriate endpoints and how should they be measured? Question # 7: What are the appropriate endpoints and how should they be measured? OS/PFS OS/PFS QOL QOL Surgical morbidity Surgical morbidity Response Response Clinical Clinical Radiologic Radiologic Serum Markers Serum Markers Surgical complete response Surgical complete response

Key Issue # 6: Proof-of-Concept designs Using neoadjuvant chemotherapy for proof-of- concept type studies Using neoadjuvant chemotherapy for proof-of- concept type studies Novel strategies Novel strategies Novel cytotoxic or biologic agents Novel cytotoxic or biologic agents Molecular mechanisms and biomarkers Molecular mechanisms and biomarkers Question # 8: Can we develop a standard queue for proof-of-concept studies in advanced ovarian cancer patients?